TEVETEN (eprosartan mesylate) by AbbVie is mechanism of action eprosartan: angiotensin ii (formed from angiotensin i in a reaction catalyzed by angiotensin-converting enzyme [kininase ii]), a potent vasoconstrictor, is the principal pressor agent of the renin-angiotensin system. Approved for hypertension. First approved in 1997.
Drug data last refreshed 4h ago · AI intelligence enriched 2w ago
TEVETEN (eprosartan mesylate) is an oral angiotensin II receptor antagonist (AT1 blocker) approved in 1997 for treatment of hypertension. It selectively blocks angiotensin II binding to AT1 receptors in vascular smooth muscle and the adrenal gland, reducing vasoconstriction and aldosterone secretion. The drug is available as a monotherapy tablet and in combination with hydrochlorothiazide (TEVETEN HCT).
As a maturing ARB monotherapy approaching loss of exclusivity, the brand team is likely transitioning from growth-focused to defensive positioning with emphasis on generic support and line extension strategies.
Mechanism of Action Eprosartan: Angiotensin II (formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme [kininase II]), a potent vasoconstrictor, is the principal pressor agent of the renin-angiotensin system. Angiotensin II also stimulates aldosterone synthesis and…
Worked on TEVETEN at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Observational Study to Investigate the Effectiveness of Eprosartan on Pulse Pressure (Teveten_MS)
Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension
Working on TEVETEN as a pharma professional means joining a mature, defensive brand team at AbbVie focused on protecting market share against generics and branded competitors. Career trajectory is typically lateral or transitional—used as a stable, lower-risk assignment before moving to high-growth launches or specialty products.